Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
LALandos Biopharma, Inc. logo

Landos Biopharma, Inc. (LABP)

NASDAQ Global Market · Currency in USD
$22.93 ▲ +0.13 (+0.57%)
At close: May 23, 4:00 PM ET. Market closed.
$22.91 ▼ -0.02 (-0.09%)
After hours: May 23, 4:37 PM ET

Summary

Previous Close
$22.80
Open
$22.93
Day's Range
$22.75 – $22.94
52 Week Range
$3.15 – $22.94
Volume
50,899
Avg. Volume
26,062
Market Cap
$71.68M
Beta (5Y Monthly)
0.14
PE Ratio (TTM)
--
EPS (TTM)
-$3.50
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Landos Biopharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
19
CEO
Gregory Oakes

Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis.

Earnings

DateEst.Actual
May 9, 2024-$1.00-$1.43Miss
Mar 21, 2024-$0.91-$0.99Miss
Nov 9, 2023-$0.79-$0.94Miss
Aug 9, 2023-$1.10-$0.63Beat
May 12, 2023-$1.00-$0.90Beat
Mar 23, 2023-$1.50-$1.30Beat

Analyst view

Rating: Hold
Buy 29% · Hold 57% · Sell 14%

Get free alerts on LABP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.